VIRI News and Press, Virios Therapeutics Inc. From 03/24/23

2023-03-24 15:03:29 ET Penny stock investing offers potential rewards and volatility. Generally, penny stocks are valued below $5 and can be risky, but they provide substantial gains for risk-tolerant investors. As March 2023 concludes, the stock market faces turbulence due to the recen...

2023-03-14 07:11:46 ET Virios Therapeutics press release ( NASDAQ: VIRI ): Q4 GAAP EPS of -$0.11 beats by $0.04 . As of December 31, 2022, Virios Therapeutics’ cash totaled $7.0 million. The Company believes it will have sufficient resources to support the Long-...

ATLANTA, March 14, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”),...

ATLANTA, March 07, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), announced today that it ...

ATLANTA, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia (“FM”), announced tod...

The definition of penny stocks typically includes small companies and cheap stocks trading for less than $5 per share. But if you’ve been trading for more than a month, you already know that it is just the tip of the iceberg regarding these low-priced stocks. In most cases, especia...

ATLANTA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia (“FM”), announced tod...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia , today announced that Greg Duncan, Chairman and CEO of Virios Ther...

Virios Therapeutics, Inc. (VIRI) Q3 2022 Earnings Conference Call November 14, 2022 08:30 AM ET Company Participants Greg Duncan - CEO Ralph Grosswald - SVP, Operations Angela Walsh - SVP, Finance & Treasurer Dr. Mike Gendreau - Chief Medical Officer ...

Virios Therapeutics press release ( NASDAQ: VIRI ): Q3 GAAP EPS of -$0.28 beats by $0.21 . As of September 30, 2022, Virios Therapeutics’ cash totaled $9.8 million. The Company believes it will have sufficient resources to support the Long-COVID exploratory prog...